Checklist Ensures Adherence to Recommended CAR-T Cell Administration Processes
How one facility ensures compliance with a complex treatment protocol.
CAR-T Therapy
AFP SPEAR T-Cells Deemed Safe in First 2 Treated Patients With Hepatocellular Carcinoma
This first-in-human trial will enroll up to 24 patients.
CAR-T Therapy Active in Malignant Pleural Mesothelioma
Future studies will look at combining the therapy with anti-PD1 blockade.
Understanding the Limitations of CAR-T Cell Therapies
CAR-T’s inability to induce durable remissions in many patients is a barrier to the success of these adoptive cell therapies—but solutions are under way.
Novel Toxicities, Anticancer Activity of Anti-CD22 CAR-T Therapies Revealed
Hemophagocytic lymphohistiocytosis is a rare, but potentially fatal, complication of immunotherapy, resulting from immune hyperactivation.
Severe Neurotoxicity Following CAR-T Cell Therapy Associated With Poor Prognosis
CAR-T–related neurotoxicity was found to be associated with the presence of cytokine release syndrome.
“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
Birinapant Found to Enhance Antitumor Activity of CAR-T in Solid Tumor Models
This study provides evidence that birinapant could enhance sensitivity to TNF, effectively boosting the activity of CAR-T therapy in solid tumors.
Next post in Breast Cancer
